Nisha Nagarsheth

7.1k total citations · 3 hit papers
16 papers, 4.8k citations indexed

About

Nisha Nagarsheth is a scholar working on Oncology, Immunology and Molecular Biology. According to data from OpenAlex, Nisha Nagarsheth has authored 16 papers receiving a total of 4.8k indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Oncology, 8 papers in Immunology and 5 papers in Molecular Biology. Recurrent topics in Nisha Nagarsheth's work include CAR-T cell therapy research (6 papers), Cancer Immunotherapy and Biomarkers (5 papers) and Immunotherapy and Immune Responses (4 papers). Nisha Nagarsheth is often cited by papers focused on CAR-T cell therapy research (6 papers), Cancer Immunotherapy and Biomarkers (5 papers) and Immunotherapy and Immune Responses (4 papers). Nisha Nagarsheth collaborates with scholars based in United States, China and Poland. Nisha Nagarsheth's co-authors include Weiping Zou, Max S. Wicha, Ilona Kryczek, Jing‐Yuan Fang, Danfeng Sun, Jie Hong, Yanan Yu, Haoyan Chen, Yun Qian and Fangfang Guo and has published in prestigious journals such as Nature, Cell and Journal of Clinical Oncology.

In The Last Decade

Nisha Nagarsheth

16 papers receiving 4.8k citations

Hit Papers

Fusobacterium nucleatum Promotes Chemoresistance to Color... 2015 2026 2018 2022 2017 2017 2015 500 1000 1.5k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Fusobacterium nucleatum Promotes Chemoresistance to Colorectal Cancer by Modulating Autophagy
    2017 1.6k citations Fangfang Guo, Yanan Yu et al. Cell profile →
  2. Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy
    2017 1.6k citations Nisha Nagarsheth, Max S. Wicha et al. Nature reviews. Immunology profile →
  3. Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy
    2015 893 citations Dongjun Peng, Ilona Kryczek et al. Nature profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Nisha Nagarsheth United States 12 2.4k 2.3k 1.8k 644 594 16 4.8k
Beth A. Helmink United States 19 2.0k 0.8× 2.8k 1.2× 1.1k 0.6× 534 0.8× 493 0.8× 42 4.5k
Jonathan M. Pitt France 18 1.6k 0.7× 2.0k 0.9× 1.8k 1.0× 971 1.5× 514 0.9× 24 4.1k
Pedro Berraondo Spain 36 2.9k 1.2× 1.8k 0.8× 3.3k 1.8× 387 0.6× 451 0.8× 164 5.9k
Takuya Osada United States 42 2.0k 0.8× 2.7k 1.2× 2.1k 1.2× 1.1k 1.7× 417 0.7× 117 5.5k
Jie Wang China 30 1.6k 0.7× 2.1k 0.9× 1.3k 0.7× 939 1.5× 457 0.8× 136 4.7k
Yuanyuan Zha United States 22 4.5k 1.9× 2.5k 1.1× 3.2k 1.8× 462 0.7× 826 1.4× 67 6.8k
Eyad Elkord United Kingdom 41 4.3k 1.8× 2.2k 1.0× 3.9k 2.1× 950 1.5× 1.1k 1.9× 126 7.7k
Masoud H. Manjili United States 35 2.2k 0.9× 1.7k 0.8× 2.6k 1.4× 561 0.9× 295 0.5× 124 4.7k
Hua Liang China 29 4.1k 1.7× 2.2k 1.0× 4.1k 2.3× 626 1.0× 1.2k 2.1× 79 7.9k
Ravid Straussman Israel 20 1.8k 0.8× 3.7k 1.6× 588 0.3× 726 1.1× 511 0.9× 28 5.3k

Countries citing papers authored by Nisha Nagarsheth

Since Specialization
Citations

This map shows the geographic impact of Nisha Nagarsheth's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nisha Nagarsheth with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nisha Nagarsheth more than expected).

Fields of papers citing papers by Nisha Nagarsheth

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nisha Nagarsheth. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nisha Nagarsheth. The network helps show where Nisha Nagarsheth may publish in the future.

Co-authorship network of co-authors of Nisha Nagarsheth

This figure shows the co-authorship network connecting the top 25 collaborators of Nisha Nagarsheth. A scholar is included among the top collaborators of Nisha Nagarsheth based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nisha Nagarsheth. Nisha Nagarsheth is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

16 of 16 papers shown
1.
Pitter, Michael, Ilona Kryczek, Hongjuan Zhang, et al.. (2024). PAD4 controls tumor immunity via restraining the MHC class II machinery in macrophages. Cell Reports. 43(3). 113942–113942. 16 indexed citations
2.
Davies, John, Ling Zhang, Nisha Nagarsheth, et al.. (2022). Non-synergy of PD-1 blockade with T-cell therapy in solid tumors. Journal for ImmunoTherapy of Cancer. 10(7). e004906–e004906. 11 indexed citations
3.
Norberg, Scott M., Nisha Nagarsheth, Andrew Sinkoe, et al.. (2020). Safety and clinical activity of gene-engineered T-cell therapy targeting HPV-16 E7 for epithelial cancers.. Journal of Clinical Oncology. 38(15_suppl). 101–101. 13 indexed citations
4.
Mousseau, Guillaume, Rachna Aneja, Mark A. Clementz, et al.. (2019). Resistance to the Tat Inhibitor Didehydro-Cortistatin A Is Mediated by Heightened Basal HIV-1 Transcription. mBio. 10(4). 33 indexed citations
5.
Norberg, Scott M., Nisha Nagarsheth, Stacey L. Doran, et al.. (2018). Regression of Epithelial Cancers Following T Cell Receptor Gene Therapy Targeting Human Papillomavirus-16 E7. Blood. 132(Supplement 1). 492–492. 9 indexed citations
6.
Nagarsheth, Nisha, Scott M. Norberg, Stacey L. Doran, et al.. (2018). Regression of epithelial cancers in humans following t-cell receptor gene therapy targeting human papillomavirus-16 E7.. Journal of Clinical Oncology. 36(15_suppl). 3043–3043. 4 indexed citations
7.
Nagarsheth, Nisha, Max S. Wicha, & Weiping Zou. (2017). Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy. Nature reviews. Immunology. 17(9). 559–572. 1561 indexed citations breakdown →
8.
Guo, Fangfang, Yanan Yu, Tiantian Sun, et al.. (2017). Fusobacterium nucleatum Promotes Chemoresistance to Colorectal Cancer by Modulating Autophagy. Cell. 170(3). 548–563.e16. 1572 indexed citations breakdown →
9.
Kryczek, Ilona, Dongjun Peng, Nisha Nagarsheth, et al.. (2016). Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy. The Journal of Immunology. 196(1_Supplement). 213.20–213.20. 14 indexed citations
10.
Nagarsheth, Nisha, Dongjun Peng, Ilona Kryczek, et al.. (2015). PRC2 Epigenetically Silences Th1-Type Chemokines to Suppress Effector T-Cell Trafficking in Colon Cancer. Cancer Research. 76(2). 275–282. 213 indexed citations
11.
Peng, Dongjun, Ilona Kryczek, Nisha Nagarsheth, et al.. (2015). Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy. Nature. 527(7577). 249–253. 893 indexed citations breakdown →
12.
Sun, Danfeng, Yanwei Lin, Jie Hong, et al.. (2015). Th22 cells control colon tumorigenesis through STAT3 and Polycomb Repression complex 2 signaling. OncoImmunology. 5(8). e1082704–e1082704. 31 indexed citations
13.
Kryczek, Ilona, Yanwei Lin, Nisha Nagarsheth, et al.. (2015). IL-22+CD4+ T cells promote colorectal cancer stemness via STAT3 transcription factor activation and induction of the methyltransferase DOT1L (TUM10P.1022). The Journal of Immunology. 194(1_Supplement). 211.3–211.3. 2 indexed citations
14.
Kryczek, Ilona, Yanwei Lin, Nisha Nagarsheth, et al.. (2014). IL-22+CD4+ T Cells Promote Colorectal Cancer Stemness via STAT3 Transcription Factor Activation and Induction of the Methyltransferase DOT1L. Immunity. 40(5). 772–784. 297 indexed citations
15.
Mousseau, Guillaume, Mark A. Clementz, Wendy Bakeman, et al.. (2012). An Analog of the Natural Steroidal Alkaloid Cortistatin A Potently Suppresses Tat-Dependent HIV Transcription. Cell Host & Microbe. 12(1). 97–108. 159 indexed citations
16.
Mousseau, Guillaume, Mark A. Clementz, Wendy Bakeman, et al.. (2012). Potent suppression of HIV viral replication by a novel inhibitor of Tat. Retrovirology. 9(S1). 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Beth A. Helmink Breakdown of academic impact, for papers by Jonathan M. Pitt Breakdown of academic impact, for papers by Pedro Berraondo Breakdown of academic impact, for papers by Takuya Osada Breakdown of academic impact, for papers by Jie Wang Breakdown of academic impact, for papers by Yuanyuan Zha Breakdown of academic impact, for papers by Eyad Elkord Breakdown of academic impact, for papers by Masoud H. Manjili Breakdown of academic impact, for papers by Hua Liang Breakdown of academic impact, for papers by Ravid Straussman
Rankless by CCL
2026